These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 37862074

  • 21. Determinants of heterosexual men's demand for long-acting injectable pre-exposure prophylaxis (PrEP) for HIV in urban South Africa.
    Cheng CY, Quaife M, Eakle R, Cabrera Escobar MA, Vickerman P, Terris-Prestholt F.
    BMC Public Health; 2019 Jul 24; 19(1):996. PubMed ID: 31340785
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Motives of Dutch men who have sex with men for daily and intermittent HIV pre-exposure prophylaxis usage and preferences for implementation: A qualitative study.
    Bil JP, van der Veldt WM, Prins M, Stolte IG, Davidovich U.
    Medicine (Baltimore); 2016 Sep 24; 95(39):e4910. PubMed ID: 27684827
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Zero knowledge and high interest in the use of long-acting injectable pre-exposure prophylaxis (PrEP) among adolescent men who have sex with men and transgender women in two capital cities in Brazil.
    Pedrana L, Magno L, Zucchi EM, da Silva LAV, Ferraz D, Grangeiro A, Castellanos M, Brasil SA, Dourado I.
    BMC Public Health; 2022 Sep 12; 22(1):1728. PubMed ID: 36096758
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Awareness about and willingness to use long-acting injectable pre-exposure prophylaxis (LAI-PrEP) among people who use drugs.
    Shrestha R, DiDomizio EE, Kim RS, Altice FL, Wickersham JA, Copenhaver MM.
    J Subst Abuse Treat; 2020 Oct 12; 117():108058. PubMed ID: 32811633
    [Abstract] [Full Text] [Related]

  • 33. Reactions and Receptivity to Framing HIV Prevention Message Concepts About Pre-Exposure Prophylaxis for Black and Latino Men Who Have Sex with Men in Three Urban US Cities.
    Mimiaga MJ, Closson EF, Battle S, Herbst JH, Denson D, Pitts N, Holman J, Landers S, Mansergh G.
    AIDS Patient Care STDS; 2016 Oct 12; 30(10):484-489. PubMed ID: 27749110
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Potential effectiveness of long-acting injectable pre-exposure prophylaxis for HIV prevention in men who have sex with men: a modelling study.
    Marshall BDL, Goedel WC, King MRF, Singleton A, Durham DP, Chan PA, Townsend JP, Galvani AP.
    Lancet HIV; 2018 Sep 12; 5(9):e498-e505. PubMed ID: 29908917
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Will Gay and Bisexual Men Taking Oral Pre-exposure Prophylaxis (PrEP) Switch to Long-Acting Injectable PrEP Should It Become Available?
    John SA, Whitfield THF, Rendina HJ, Parsons JT, Grov C.
    AIDS Behav; 2018 Apr 12; 22(4):1184-1189. PubMed ID: 28913659
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Familiarity with and Preferences for Oral and Long-Acting Injectable HIV Pre-exposure Prophylaxis (PrEP) in a National Sample of Gay and Bisexual Men in the U.S.
    Parsons JT, Rendina HJ, Whitfield TH, Grov C.
    AIDS Behav; 2016 Jul 12; 20(7):1390-9. PubMed ID: 27000145
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.